2023
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Miao R, Kim D, Yu J, Kovari B, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. Journal Of Clinical Oncology 2023, 41: 228-228. DOI: 10.1200/jco.2023.41.4_suppl.228.Peer-Reviewed Original ResearchProgression free survivalMedian progression free survivalTreated with regorafenibOverall survivalPD-L1Tumor microenvironmentColorectal cancerMedian OSCD8 expressionPartial responseTreg cellsImmune desertPredictive biomarkersAssociated with prolonged progression free survivalMismatch repair-proficient colorectal cancersProlonged progression free survivalDisease control ratePhase I/Ib studyPredicting clinical benefitPD-L1 expressionPretreatment tumor samplesPotential predictive biomarkersPMMR colorectal cancerBiomarker-positiveBiomarker-negative patients
2022
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancer